Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pargyline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 2/20 | 1.00 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 1.00 |
| ▸ | PYCR1 | P32322 | 18/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.96 |
| ▸ | BLM | P54132 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pargyline SCHEMBL18036659 | 1.00 | PYCR1 (1.00) | PYCR1LMNAMAOBUSP2CYP3A4 | |
| Pargyline SCHEMBL121111 | 0.98 | LMNA (1.00) | PYCR1LMNAMAOBUSP2CYP3A4 | |
| Pargyline SCHEMBL7363311 | 0.98 | PYCR1 (0.96) | PYCR1LMNAMAOBUSP2CYP3A4 | |
| Pargyline SCHEMBL2657939 | 0.93 | PYCR1 (0.86) | PYCR1LMNAMAOBUSP2CYP3A4 | |
| Pargyline SCHEMBL4441967 | 0.87 | PYCR1 (0.75) | PYCR1LMNAMAOBUSP2CYP3A4 | |
| Pargyline SCHEMBL5981667 | 0.87 | PYCR1 (0.75) | PYCR1LMNAMAOBUSP2CYP3A4 | |
| SCHEMBL11896612 | 0.84 | PYCR1 (0.72) | PYCR1LMNAMAOBUSP2CYP3A4 | |
| SCHEMBL10033796 | 0.84 | PYCR1 (0.71) | PYCR1LMNAMAOBUSP2CYP3A4 | |
| SCHEMBL8244727 | 0.82 | PYCR1 (0.72) | PYCR1LMNAMAOBUSP2CYP3A4 | |
| SCHEMBL10033809 | 0.82 | PYCR1 (1.00) | PYCR1LMNAMAOBUSP2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12452 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034065-A1 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2026-02-05 | — | — | US | claimed |
| EP-4680240-A1 | METHOD OF TREATING DISORDERS WITH SURF1 MALFUNCTION | Cure Mito Foundation (US) | 2026-01-21 | — | — | EP | claimed |
| US-12472146-B2 | Extended release pharmaceutical formulation | DOUGLAS PHARMACEUTICALS, LTD. (NZ) | 2025-11-18 | — | — | US | claimed |
| WO-2025235516-A1 | DEVELOPMENT OF LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) INHIBITORS AS ANTI-CANCER REAGENTS | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2025-11-13 | — | — | WO | claimed |
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | Natural MedTech Pty Ltd (AU) | 2025-11-06 | — | — | US | claimed |
| EP-4618981-A1 | COMBINATIONS OF MONOAMINE OXIDASE INHIBITORS AND SEROTONIN RECEPTOR AGONISTS AND THEIR THERAPEUTIC USE | Remedi, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4615444-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural Medtech Pty Ltd (AU) | 2025-09-17 | — | — | EP | claimed |
| WO-2025151706-A1 | EPIGENETIC REAGENTS AND UTILIZATION OF CAR NK CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-07-17 | — | — | WO | claimed |
| US-12350379-B2 | Extended release pharmaceutical formulation and methods of treatment | DOUGLAS PHARMACETICALS LTD (NZ) | 2025-07-08 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-4555503-A | ANGIOTENSIN INHIBITORS | MERCK & CO., INC. (US) | 1985-11-26 | — | — | US | claimed |
| EP-0157409-A2 | Renin inhibitors containing 2-substituted statine | MERCK & CO. INC. (US) | 1985-10-09 | — | — | EP | claimed |
| EP-0156318-A2 | C-terminal amide cyclic renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0156322-A2 | Renin inhibitors containing peptide isosteres | MERCK & CO. INC. (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0129189-A2 | Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
| US-4472380-A | CARBOXYALKYL DIPEPTIDE DERIVATIVES | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | claimed |
| EP-0107095-A1 | 1-N-alkylcarboxy-benzofused lactams useful as antihypertensive agents | MERCK & CO. INC. (US) | 1984-05-02 | — | — | EP | claimed |
| EP-0081094-A1 | Substituted omega-amino-carboxymethyldipeptide antihypertensive agents | MERCK & CO. INC. (US) | 1983-06-15 | — | — | EP | claimed |
| EP-0079522-A1 | N-Carboxymethyl(amidino)lysyl-proline antihypertensive agents | MERCK & CO. INC. (US) | 1983-05-25 | — | — | EP | claimed |
| US-4032406-A | MEASURING OXYGEN-UPTAKE VIA HYDROXYLATION OF DOPAMINE OR TYRAMINE; ASCORBATE, FUMARATE | MONSANTO COMPANY (US) | 1977-06-28 | — | — | US | claimed |